StemImmune LLC

Call Directions Website

StemImmune LLC Stem Cells and Immuno-Therapy Cytokines and Media and related Products.

🧬 In Vivo CAR-NK Engineering: A Breakthrough—but Can It Deliver Long-Term Cancer Protection?A recent Nature Biotechnolog...
10/16/2026

🧬 In Vivo CAR-NK Engineering: A Breakthrough—but Can It Deliver Long-Term Cancer Protection?

A recent Nature Biotechnology study explores an exciting approach: engineering CAR-NK cells directly inside the body using targeted lipid nanoparticles (LNPs).

This could represent an important step toward simplifying cancer immunotherapy.

But successful CAR delivery is only the beginning.

What happens when CAR expression fades?

Can engineered NK cells survive, expand, and maintain their ability to fight cancer?

In our latest StemImmune Perspective, we examine the biological challenges that remain:

🔬 NK-cell availability after chemotherapy
🧬 Tissue-specific NK-cell expansion
🛡️ IL-15 signaling and NK-cell persistence
🎯 Sustained tumor control
🧠 Long-term immune memory

Engineering immune cells is one challenge. Keeping them functional long enough to protect patients is another.

📖 Read our full analysis:
https://stem-immune.com/in-vivo-car-nk-long-term-immune-protection

📚 Zenodo DOI:
https://doi.org/10.5281/zenodo.23409123

We often ask, “How can we engineer a stronger oncolytic virus?”But the more important question may be:Where should we de...
10/06/2026

We often ask, “How can we engineer a stronger oncolytic virus?”

But the more important question may be:
Where should we deliver it, which lesion should we choose, and what should come next?
In our latest StemImmune Perspective, we examine clinical signals from T-VEC, PVSRIPO, G47Δ, DNX-2401, Pexa-Vec, and VCN-01 and propose a testable framework:
Delivery route × lesion selection → local tumor debulking → immune priming → biology-guided sequential immunotherapy → control of minimal residual disease → durable survival

The key idea is simple: local oncolysis alone is not enough. The goal may be to use OV therapy to change the tumor, release autologous antigens, activate immunity, and then choose the next immune intervention based on the new biological state.

This is not yet an established clinical paradigm. It is a hypothesis for prospective testing.
OS remains the final test.

Read the full article:
stem-immune.com/rethinking-oncolytic-virus-therapy-delivery-lesion-selection-mrd
DOI: 10.5281/zenodo.23183034

Can lupus treatment move from immune suppression to immune reset?A recent Phase 1 study using the CD3×CD19 bispecific an...
09/24/2026

Can lupus treatment move from immune suppression to immune reset?

A recent Phase 1 study using the CD3×CD19 bispecific antibody A-319 in systemic lupus erythematosus (SLE) raises an important possibility: perhaps the goal is not only to suppress inflammation, but to disrupt the pathological immune network that keeps the disease going.

In our new StemImmune Perspective, we look at SLE as a self-reinforcing loop involving autoreactive B cells, autoantibodies, immune complexes, IFN-I, BAFF, and tissue inflammation.

We then ask a bigger question:

Why do some treatments simply control the loop, while deeper B-cell depletion may create an opportunity for the immune system to rebuild?

Our proposed framework:

Suppress → Deplete → Rebuild → Reset

The most important endpoint may not be whether B cells disappear.

It may be whether B cells can return without lupus returning.

Read the full article:
https://stem-immune.com/breaking-autoimmune-loop-cd3-cd19-sle-immune-reset

Can we really generate a true human long-term hematopoietic stem cell from iPSCs?The field has made major progress in gu...
09/17/2026

Can we really generate a true human long-term hematopoietic stem cell from iPSCs?

The field has made major progress in guiding pluripotent stem cells through mesoderm, hemogenic endothelium, and endothelial-to-hematopoietic transition (EHT). But reaching these milestones does not necessarily mean we have created a bona fide LT-HSC with durable self-renewal and long-term multilineage function.

In our latest StemImmune Perspective, we ask whether one missing piece may be developmental history.

A nascent HSC may still need to pass through a fetal-liver-like maturation phase, integrate niche, metabolic, mechanical, and immune signals, and then complete a fetal-to-adult transition before acquiring stable adult-type LT-HSC properties.

We propose a broader framework:

HSC generation → HSC maturation → fetal-to-adult transition → LT-HSC maintenance and expansion

The Perspective also introduces an isogenic “seed-and-soil” strategy, emphasizes dose × duration × withdrawal timing, and discusses how developmental trajectory drift may emerge during scale-up and manufacturing.

Read the full Perspective:
https://stem-immune.com/reconstructing-human-lt-hsc

DOI:
https://doi.org/10.5281/zenodo.22816532

☘️We can make heart cells from iPSCs that beat. But can they truly replace damaged heart muscle?That gap is much larger ...
09/01/2026

☘️We can make heart cells from iPSCs that beat. But can they truly replace damaged heart muscle?

That gap is much larger than it first appears.

iPSC-derived cardiomyocytes often remain fetal-like in their electrophysiology, metabolism, structure, and contractile function. Recent advances in cardiac organoids and engineered heart tissues suggest that maturation may depend on something we have underestimated: the developmental environment surrounding the cell.

HSCs develop through the fetal liver. T cells require thymic education. Could heart cells also need a developmental “education” before becoming truly functional adult tissue?

Our latest StemImmune Perspective explores the journey from cell identity to cell function.

Could humans one day regrow a lost limb?A fascinating new study published in Science suggests the answer may not be “imp...
04/13/2026

Could humans one day regrow a lost limb?

A fascinating new study published in Science suggests the answer may not be “impossible.”

Researchers found that mammals may still carry the hidden genetic program needed for limb regeneration—but it is switched off because our cells are too sensitive to oxygen.

When mouse limb tissue was placed in a lower-oxygen environment, it began to act more like a regenerating salamander limb:

✓ Faster wound closure
✓ Activation of the HIF1A pathway
✓ Regenerative genes turned back on
✓ Less scarring and abnormal cartilage formation

Even more exciting, when low oxygen was combined with specific growth factors, the tissue began expressing key genes required for limb regeneration.

The implication is remarkable: humans may not have lost the ability to regenerate—we may simply have locked it away.

While true human limb regrowth is still far in the future, this study opens a new path for regenerative medicine, tissue engineering, and advanced wound healing.

Read more on StemImmune’s latest blog: stem-immune.com/blog

Address

179 Contractors Street
Livermore, CA
94551

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+16507226613

Website

Alerts

Be the first to know and let us send you an email when StemImmune LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category